ESG

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

The pipeline giant's record $20B EBITDA is fueled by traditional energy, while it aggressively expands into renewables to power the digital economy.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

Byreal's 2026 roadmap, revealed at Solana Accelerate, promises AI-driven liquidity and 24/7 real-world asset trading, aiming to woo institutions.

A new 'Wuthering Heights' film arrives, but its true story may be its surprising link to the global phenomenon of the telenovela. How did it happen?

Vibrant festivals in Cairo and Rabat celebrate the Chinese New Year, revealing a strategic cultural diplomacy effort to deepen ties in the Middle East.

Helion's Polaris prototype achieves a private industry first with 150M°C plasma and D-T fusion, accelerating its plan to power Microsoft by 2028.

Aktiia's Hilo adds sleep and step tracking to its validated blood pressure monitor, promising a holistic view of heart health in a competitive market.

As Guardian Pharmacy Services prepares for a key investor conference, it showcases strong growth while its industry faces a looming crisis. Can its model work?

As the Milan 2026 Winter Events begin, a massive new e-bike fleet and an affordable 'Champion Pass' aim to redefine sustainable urban mobility.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Vitalist reports soaring losses and a $6.4M debt surge, raising 'going concern' alarms. Can its new Reebok smartwatches and VitalOS™ platform save it?

With a 33% revenue surge and expanding margins, Capstone Green Energy's strategic pivot to data centers and EaaS is paying off, marking a major turnaround.

A new 'longevity center' in Naperville signals a growing trend in proactive health, but what does this mean for the Chicago wellness landscape?

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

With results expected to beat guidance, all eyes are on Progyny's upcoming earnings as a key indicator for the rapidly expanding corporate family-building industry.

Texas Athletics and supplement brand Humann partner to turn basketball games into a live lesson on heart health, blending science, sports, and marketing.